Jaime Blanchard
Optometrist · West Allis, WINPI 1700880499
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,876 of the $7,323 with a category attached, or 66.6%. 21 manufacturers reported payments, led by Alcon at 51.3% of the total. Reporting peaked in 2024 at $2,632 and has fallen 59.1% since, to $1,077 in 2025. Among optometrist clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $44.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$528
- Novartis$449
- Tarsus Pharmaceuticals, Inc.$388
- Bausch & Lomb Americas Inc.$327
- Dompe US, Inc.$261
- plus $2K from 15 others
What the payments were for
- Travel & lodging$2,44233%
- Food & beverage$4,87667%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 38 | $3,759 |
| AbbVie(2 entities) | 19 | $528 |
| Novartis | 33 | $449 |
| Tarsus Pharmaceuticals, Inc. | 10 | $388 |
| Bausch & Lomb Americas Inc. | 19 | $327 |
| Dompe US, Inc. | 5 | $261 |
| Amgen(2 entities) | 4 | $250 |
| Astellas Pharma US Inc | 2 | $194 |
| Glaukos Corporation | 1 | $176 |
| Regeneron Healthcare Solutions, Inc. | 2 | $152 |
| Harrow Eye, LLC | 5 | $139 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Oyster Point Pharma, Inc. | 5 | $120 |
| Sun Pharmaceutical Industries Inc. | 6 | $116 |
| Rxsight Inc | 1 | $105 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $78 |
| Thea Pharma Inc. | 3 | $56 |
| The Cameron-ehlen Group, Inc. | 1 | $40 |
| Apellis Pharmaceuticals, Inc. | 2 | $34 |
| Shire North American Group Inc | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$1,188
- DAILIES$444
- XDEMVY$239
- CE-marked KXLA system$176
- EYLEA HD$125
- EYSUVIS$125
- TEPEZZA$125
- XEN$124
- Oxervate$115
- Izervay$106
- RXSIGHT CONTACT LENS$105
- RXSIGHT INJECTOR CARTRIDGE$105
- RXSIGHT INJECTOR HANDPIECE$105
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$105
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$105
How this compares
$7,323 in reported general payments places this provider in the 95th percentile of 867 optometrist providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 124 | $135,238 |
| LumiganBimatoprost | 136 | $85,396 |
| XiidraLifitegrast | 47 | $68,898 |
| Cyclosporine | 48 | $31,548 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $15,076 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $10,352 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $8,326 |
| RhopressaNetarsudil Mesylate | 20 | $7,970 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $7,821 |
| VyzultaLatanoprostene Bunod | 14 | $6,113 |
| Travoprost | 53 | $5,309 |
| Latanoprost | 303 | $3,471 |
| Epinastine Hcl | 31 | $1,887 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 46 | $1,821 |
| Fluorometholone | 19 | $1,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $528 | $228,960283 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $327 | $75,01161 claims |
| AlconSimbrinza | $3,759 | $10,35233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 867 optometrist providers in Wisconsin.
Other optometrist in West Allis
- Eric KnightWest Allis$6K
- Joel HansenWest Allis$5K
- David NelsonMadison$256K
- Jennifer FrieheMukwonago$234K
- Tessa SokolMadison$105K
- Christopher LopezClintonville$48K
- Jeff BanasMount Pleasant$46K
- Jessica SchiffbauerKenosha$27K
- Jeffrey ClementsSun Prairie$16K
- Douglas HinsonSturtevant$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.